BioXcel Therapeutics (BTAI)
(Real Time Quote from BATS)
$3.49 USD
+0.52 (17.51%)
Updated Aug 6, 2025 03:18 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BTAI 3.49 +0.52(17.51%)
Will BTAI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BTAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BTAI
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
BTAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates
Other News for BTAI
BioXcel Therapeutics announces publication on active ingredient in BXCL-501
BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of ...
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session